Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren

By /

Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide catch up?

Scroll to Top